275 related articles for article (PubMed ID: 21837775)
1. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
[TBL] [Abstract][Full Text] [Related]
2. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
3. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
Hodgkins P; Yen L; Yarlas A; Karlstadt R; Solomon D; Kane S
Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
[TBL] [Abstract][Full Text] [Related]
4. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
5. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
6. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
[TBL] [Abstract][Full Text] [Related]
7. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
9. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Inflamm Bowel Dis; 2009 Jan; 15(1):1-8. PubMed ID: 18671232
[TBL] [Abstract][Full Text] [Related]
10. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst SN; Kane S
Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
[TBL] [Abstract][Full Text] [Related]
11. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis.
Boyle M; Ting A; Cury DB; Nanda K; Cheifetz AS; Moss A
Inflamm Bowel Dis; 2015 Dec; 21(12):2873-8. PubMed ID: 26313693
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
[TBL] [Abstract][Full Text] [Related]
13. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
14. Multi-matrix system mesalamine: to use or not to use.
Kale-Pradhan PB; Pradhan RS; Wilhelm SM
Ann Pharmacother; 2008 Feb; 42(2):265-9. PubMed ID: 18182473
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
[TBL] [Abstract][Full Text] [Related]
16. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
17. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
18. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
19. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
Yarlas A; D'Haens G; Willian MK; Teynor M
Inflamm Bowel Dis; 2018 Jan; 24(2):450-463. PubMed ID: 29361097
[TBL] [Abstract][Full Text] [Related]
20. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
